Navigation Links
Study Finds Folic Acid Not Cardioprotective, Though Safe
Date:11/11/2008

the United States, Canada and several other countries that require folic acid fortification of flour, bread and many cereals to protect newborns from neural tube defects, Armitage said.

At the same late breaking clinical trials session, Armitage's co-principal investigator, Professor Rory Collins, professor of medicine and epidemiology at the University of Oxford, presented a second randomized comparison from the SEARCH trial of 80mg versus 20mg per day of simvastatin -- the largest direct comparison of more versus less intensive lowering of low-density lipoprotein cholesterol (LDL-C).

Previous studies have found that statin therapy reduces the relative risk of MVE by about 20 percent per 40 milligram per deciliter (mg/dL) reduction in LDL-C. Compared with the patients assigned 20mg per day of simvastatin in SEARCH, LDL-C was reduced by an average of 14mg/dL more among the patients assigned 80mg per day of simvastatin.

Collins presented the results of SEARCH in the context of an update of a meta-analysis of individual patient data from previous studies of statin therapy published in The Lancet in 2005 (Lancet 2005 Oct 8: 366:1267-78.) Based on that meta-analysis, a 14 mg/dL greater reduction in LDL-C would be expected to produce a 6 percent to 7 percent relative reduction in MVE, which is what researchers observed in the SEARCH trial.

Daily doses of 80mg simvastatin were associated with more myopathy cases than 20mg simvastatin, although the SEARCH trial had identified a genetic variant that accounted for much of the excess myopathy risk with the higher-dose simvastatin regimen.

Co-authors are the SEARCH Collaborative Group. Individual author disclosures are available on the abstract.

The University of Oxford's Clinical Trial Service Unit designed, conducted, analyzed and interpreted the SEARCH study, which was funded by a research grant from Merck & Co.

Statements and conclusions of study authors that are presented a
'/>"/>

SOURCE American Heart Association
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Study Finds Timing Is Everything For Some Heart Attack Patients
2. New technique to study the genetics of breast cancer
3. Intestinal Infection Afflicts 13 of 1,000 Hospital Patients, Infection Rates 6.5 - 20 Times Greater Than Previous Estimates, New Study Says
4. WomenHeart Urges Women to Talk With Doctors About New Study Showing Statins Prevent Heart Attacks, Deaths
5. High Temps Degrade Contact Lens Solution: Study
6. Study Upholds Stopping Plavix Use Before Surgery
7. Cornell researchers study showing evidence of a major environmental trigger for autism
8. Study confirms increased heart attack deaths in NYC ambulance diversions
9. Study improves recovery for mothers with depression
10. Companies Pay a High Price for Employees With Crohns Disease and Ulcerative Colitis, According to Study From Thomson Reuters
11. Study Finds Rise in Rate of Diagnostic Imaging in Managed Care
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy 2Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 2Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 4Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 5Frost 26amp 3B Sullivan Recognizes Fovia for its HDVR 28R 29 Platform A Disruptive Technology Breakthrough 6205 1Frost 26amp 3B Sullivan Recognizes Fovia for its HDVR 28R 29 Platform A Disruptive Technology Breakthrough 6205 2Frost 26amp 3B Sullivan Recognizes Fovia for its HDVR 28R 29 Platform A Disruptive Technology Breakthrough 6205 3Frost 26amp 3B Sullivan Recognizes Fovia for its HDVR 28R 29 Platform A Disruptive Technology Breakthrough 6205 4Colorado MRI Clinic Blends Ultra Patient Care with Significant Cost Savings 6201 1Colorado MRI Clinic Blends Ultra Patient Care with Significant Cost Savings 6201 2Colorado MRI Clinic Blends Ultra Patient Care with Significant Cost Savings 6201 3Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 1Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 2Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 3Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 4Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 5Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 6